Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide1.
These challenging disorders are genetically complex, often harboring a range of somatic mutations. In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases.
Traditional molecular testing involves iterative single-analyte approaches, complex workflows, all of which results in variable, often lengthy, turnaround times.
Next-generation sequencing (NGS) has revolutionized the study of hematologic malignancies by streamlining genetic profiling. NGS allows for efficient, simultaneous assessment of multiple genetic biomarkers with a single assay. Advancements in NGS automation enable results to now be available in as fast as 1-2 days.
Watch a brief video to see how the Ion Torrent Genexus System can deliver rapid results with minimal user intervention for myeloid samples.
Deepen your understanding of hematological malignancies with an unmatched offering of NGS testing solutions and capabilities. We offer a range of NGS assays for applications across a spectrum of disease research areas. Each assay is provided as part of a complete solution on our trusted NGS platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.
Integrated analysis software streamlines reporting and facilitates the interpretation of results. Unmatched workflow automation simplifies the testing process, enabling any laboratory to adopt NGS testing—including those without prior experience and expertise.
Our customers and collaborators are making incredible research advancements, disrupting traditional paradigms, and bringing forth new insights and approaches for understanding hematologic malignancies. Our NGS technology has been embraced by some of the top minds in the world to address the most pressing challenges is these disease research areas.
A New Day for Myeloid
Dr. Kojo Elenitoba-Johnson
University of Pennsylvania
Achieving Success in the MoDx: The Molecular Hematopathology Perspective
Dr. Yi Ding, Geisinger Medical Laboratories
Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasm
Dr. John DeCoteau, University of Saskatchewan
NGS for B Cell Receptor Sequencing in Multiple Myeloma
Dr. Arthur Kowalik, Holy Cross Cancer Center
Lymphoma Molecular Characterization - Assessing the Journey to Answers
Dr. Marianne Grantham, Barts Health NHS Trust
Dr. Craig Mackinnon
University of Alabama at Birmingham
How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms
Dr. Bevan Tandon
Sung H et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21660
For Research Use Only. Not for use in diagnostic procedures.